MDxHealth SA (MXDHF) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Company Participants Michael McGarrity - CEO Ron Kalfus - CFO Conference Call Participants Francois Brisebois - Oppenheimer Mark Massaro - BTIG Thomas Franken - KBC Securities Operator Greetings. Welcome to the MDxHealth Fourth Quarter and Full Year 2022 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note th ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from _________ to _________ OR ☐ SHELL COMPANY REPORT PURSUANT TO SE ...

Financial Data and Key Metrics Changes - Q4 2021 revenue grew by 46% compared to Q4 2020, while full-year 2021 revenue increased by 20% over the previous year, reaching $22.2 million [4][11] - Services revenue amounted to $21.9 million, a 21% increase from $18.1 million in 2020, with ConfirmMDx representing over 90% of service revenue [11][12] - Gross margins improved to 47.5% in 2021 from 43.6% in 2020, reflecting a growth margin improvement of 390 basis points [12] Business Line Data and Key Metrics Changes - The company experienced modest test volume increases in 2021 despite pandemic challenges, with accelerated revenue growth attributed to improved revenue cycle management and higher average selling prices [7][11] - The introduction of a urinary tract infection (UTI) testing service in Q4 2021 is expected to contribute to revenue in 2022, with early adoption indicators being positive [9][10] Market Data and Key Metrics Changes - Prostate cancer screening rates were estimated to be down 50% due to the pandemic, impacting patient flow and sales rep access [4][5] - The company anticipates a return to pre-pandemic volumes for both Confirm and Select tests as restrictions ease and patient flow returns [5][6] Company Strategy and Development Direction - The company aims to expand its menu into active surveillance, providing additional growth opportunities, with updates expected mid-year [16][17] - The management emphasizes a commitment to execution and sustainable growth, aiming to drive adoption of clinical pathways and enhance payer coverage [15][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence that headwinds from the pandemic will turn into growth-driving tailwinds in 2022, with expectations for revenue between $25 million and $27 million [3][16] - The management highlighted the importance of the final Medicare coverage decision for SelectMDx tests, which is expected to contribute to revenue in the second half of 2022 [16][27] Other Important Information - The company ended 2021 with $58.5 million in cash, bolstered by equity raises and an initial public offering [14] - Operating expenses for 2021 were $37.4 million, up 6% from 2020, primarily driven by R&D expenses related to future product pipelines [12][13] Q&A Session Summary Question: Impact of Omicron on Test Volumes - Management acknowledged challenges from Omicron but noted a return in patient flow and sales rep access, expecting improvements as they move into Q2 [20][21] Question: Timing for Active Surveillance Program Launch - Management indicated that visibility on key drivers will improve by mid-year, but no revenue contribution from active surveillance is expected in 2022 [22][23] Question: UTI Testing Reimbursement and ASP - Management confirmed positive early experiences with UTI testing and is gathering data on reimbursement rates to provide future guidance [31][34] Question: Sales Force Expansion Opportunities - Management stated that current revenue guidance does not imply additional sales force expansion, but they are prepared to accelerate growth if patient flow returns [35][37] Question: SelectMDx and ConfirmMDx Adoption - Management expressed confidence in the growth potential of both tests, with SelectMDx expected to drive unit growth due to its larger market size [41][42] Question: UTI Testing Volume and Reimbursement - Management confirmed that UTI testing has been fully launched and is expected to contribute to revenue, with ongoing analysis of reimbursement landscapes [49][50] Question: Select Test and LCD Coverage - Management views the anticipated LCD coverage as a catalyst for broader commercial payer coverage, similar to past experiences with ConfirmMDx [53][54]

February 2022 Corporate Presentation MDxHealth® Forward looking statement This presentation contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are be ...

MDxHealth SA (MXDHF) Q2 2021 Results Conference Call August 26, 2021 1:00 PM ET Company Participants Michael McGarrity - CEO Ron Kalfus - CFO Conference Call Participants Lenny Van Steenhuyse - KBC Securities Susan Chor - Oppenheimer Laura Roba - Degroof Petercam Operator Good day ladies and gentlemen, and welcome to MDxHealth Half Year Release of Results and Business Update Conference Call. As a reminder, this conference call is being recorded. Before we begin, I would like to remind everyone that the Comp ...

MDxHealth SA (MXDHF) Q2 2020 Earnings Conference Call August 26, 2020 2:00 AM ET Company Participants Michael McGarrity - Chief Executive Officer Ron Kalfus - Chief Financial Officer Conference Call Participants Operator Ladies and gentlemen, thank you for standing by. Welcome to MDxHealth First Half 2020 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] I must advise you tha ...

MDxHealth SA (MXDHF) Q4 2019 Earnings Conference Call February 26, 2020 3:00 AM ET Company Participants Michael McGarrity - Chief Executive Officer Ron Kalfus - Chief Financial Officer Conference Call Participants Lenny Van Steenhuyse - KBC Securities NV Alex Cogut - Kempen & Co Operator Ladies and gentlemen, thank you for standing by, and welcome to the MDxHealth Full Year 2019 Results Conference Call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a ...

MDxHealth SA (MXDHF) Q2 2019 Results Earnings Conference Call August 29, 2019 5:00 AM ET Company Participants Michael McGarrity - Chief Executive Officer Ron Kalfus - Chief Financial Officer Conference Call Participants Lenny Van Steenhuyse - KBC Securities Operator Good morning ladies and gentlemen. Thank you for standing by. Welcome to the MDxHealth half year 2019 results conference call. At this time, all participants are in a listen-only mode. There will be a presentation followed by a question-and-answ ...